Daré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in June
Dare Bioscience, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $2.19
+7.4% in 3d after detection
Post-detection moves
1h
—
1d
-2.8%
3d
+7.4%
7d
+7.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS